lynparza
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
European green light for Lynparza in germline BRCA-mutated metastatic pancreatic cancer
July 8, 2020Research and Development, Sales and Marketing AstraZeneca, Cancer, Europe, MSD, lynparza
The European Commission has awarded approval to AstraZeneca and MSD’s Lynparza (olaparib) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer, with …
Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer
June 1, 2020Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza
Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …
Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer
May 11, 2020Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer
Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …
Japan grants orphan drug designation to Lynparza for BRCA+ unresectable pancreatic cancer
March 19, 2020Research and Development, Sales and Marketing AstraZeneca, Japan, lynparza, pharma
AstraZeneca has confirmed that its PARP inhibitor Lynparza (olaparib) has been awarded orphan drug designation in Japan for the maintenance …
AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer
March 13, 2020Medical Communications, Research and Development AstraZeneca, cediranib, lynparza, pharma, trial failure
Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined …
Lynparza secures accelerated FDA review for metastatic castration-resistant prostate cancer
January 20, 2020Sales and Marketing Cancer, FDA, lynparza, pharma
Following the recommendation of the tablet formulation of the drug for use on the NHS in England and Wales, news …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
FDA advisory committee approves the use of Lynparza in pancreatic cancer
December 18, 2019Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations
August 14, 2019Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial
August 7, 2019Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer
AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer
June 18, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
